Literature DB >> 7226168

Cardiomyopathy and other chronic toxic effects induced in rabbits by doxorubicin and possible prevention by coenzyme Q10.

N Domae, H Sawada, E Matsuyama, T Konishi, H Uchino.   

Abstract

Cumulative dose-dependent toxic effects, particularly cardiomyopathy, induced by doxorubicin and the possible prevention by coenzyme Q10 (CoQ10) were studied in rabbits. In rabbits given doxorubicin alone, there was considerable body weight loss, alopecia, pancytopenia, significant increase in serum creatine phosphokinase and LDH, and ECG changes characterized by tachycardia, flat and inverted T wave, the premature ventricular contractions. In rabbits given doxorubicin plus CoQ10, the only change was pancytopenia. In rabbits treated with doxorubicin alone, the most prominent histologic changes were observed in mitochondria of myocytes, and these changes were characterized by loss of outer membrane, disarrangement of cristae, and formation of numerous concentric lamellae. In addition to mitochondrial changes, there were numerous vacuolizations and extensive depositions of both electron-dense and membranous laminated bodies in the sarcoplasm and disarrangement of Z-band and filamentous changes of myofibrils. Numerous vacuolizations in the capillary endothelial cytoplasm in the myocardium were also conspicuous. On the other hand, few significant morphologic changes were seen in the nuclei of myocytes. There were few ECG and histopathologic changes in rabbits treated with both doxorubicin and CoQ10. These findings suggest that the cardiomyopathy of doxorubicin may be prevented or is at least inhibited by CoQ10. The mechanisms of both doxorubicin-induced cardiomyopathy and its prevention by CoQ10 are discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7226168

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  6 in total

1.  Coenzyme q10 therapy.

Authors:  Juan Garrido-Maraver; Mario D Cordero; Manuel Oropesa-Ávila; Alejandro Fernández Vega; Mario de la Mata; Ana Delgado Pavón; Manuel de Miguel; Carmen Pérez Calero; Marina Villanueva Paz; David Cotán; José A Sánchez-Alcázar
Journal:  Mol Syndromol       Date:  2014-07

2.  Acute cardiac toxicity in patients after doxorubicin treatment and the effect of combined tocopherol and nifedipine pretreatment.

Authors:  R Lenzhofer; U Ganzinger; H Rameis; K Moser
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

3.  Covalent protein binding of reactive adriamycin metabolites in rat liver and rat heart microsomes.

Authors:  M E Scheulen; H Kappus; A Nienhaus; C G Schmidt
Journal:  J Cancer Res Clin Oncol       Date:  1982       Impact factor: 4.553

Review 4.  Doxorubicin (adriamycin) cardiomyopathy.

Authors:  E Saltiel; W McGuire
Journal:  West J Med       Date:  1983-09

Review 5.  Reversing mitochondrial dysfunction, fatigue and the adverse effects of chemotherapy of metastatic disease by molecular replacement therapy.

Authors:  Garth L Nicolson; Kenneth A Conklin
Journal:  Clin Exp Metastasis       Date:  2007-12-05       Impact factor: 5.150

6.  Effects of coenzyme Q10 supplementation on inflammation, angiogenesis, and oxidative stress in breast cancer patients: a systematic review and meta-analysis of randomized controlled- trials.

Authors:  Mina Alimohammadi; Ali Rahimi; Fatemeh Faramarzi; Monireh Golpour; Reza Jafari-Shakib; Reza Alizadeh-Navaei; Alireza Rafiei
Journal:  Inflammopharmacology       Date:  2021-05-18       Impact factor: 4.473

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.